Risk Factors for Barotrauma in COVID-19

Hospital General Ajusco Medio

Status: Completed

Conditions: Barotrauma; Covid19

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT04859881

HGAM01

Details and patient eligibility

About

Barotrauma in mechanical ventilation (MV) is defined as lung damage attributable to the application of high airway pressure and is one of the potential mechanisms of ventilator-induced lung injury (VILI). Previous studies have shown an increased mortality in patients with barotrauma under MV; pneumothorax (PTX) being the most common presentation, but it can also present as pneumomediastinum (PM) with or without PTX, with extension to soft tissue as subcutaneous emphysema or even as pneumo-retroperitoneum and pneumo-scrotum.

Traditionally, underlying lung disease or age are known risk factors for non-trauma related barotrauma. However, in patients with novel coronavirus disease (COVID-19), the incidence of this complication is more common than in non-infected patients, as recently reported. Since little is known regarding which are the main risk factors for these events to develop, most pathophysiological mechanisms remain unexplained.

The aim of this study was to determine the risk factors for developing barotrauma in patients under MV with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Secondary objectives were to determine the incidence of barotrauma and its association with mortality.

Enrollment: 262 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients under MV fulfilling the Berlin definition for ARDS, with positive SARS-COV2 real time polymerase chain reaction

Exclusion criteria

• Incomplete clinical records and other causes of extrapulmonary air

Trial design

262 participants in 2 patient groups

Barotrauma/cases

Description:

Cases were defined as patients with barotrauma consulted with the Surgery Department

Treatment:

Other: No intervention

No braotruma/Controls

Description:

Controls were selected from a random sample of the COVID-19-ARDS cohort.

Treatment:

Other: No intervention